Target family: Lanosterol biosynthesis pathway (type: enzyme)
Target: hydroxymethylglutaryl-CoA reductase

Ligand: 5-ketodihydromevinolin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 9 pIC50
Reference (Journal): Total synthesis and biological evaluation of structural analogues of compactin and dihydromevinolin.
Published in: J Med Chem

Ligand: atorvastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1996)
Primary target: yes
Median affinity: 7.849999904632568 pKi
Reference (Journal): Binding thermodynamics of statins to HMG-CoA reductase.
Published in: Biochemistry

Ligand: atorvastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1996)
Primary target: yes
Median affinity: 8.100000381469727 pIC50
Reference (Journal): Structural mechanism for statin inhibition of HMG-CoA reductase.
Published in: Science

Ligand: atorvastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1996)
Median affinity: 8.94 pIC50
Reference (Journal): Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Published in: Am J Cardiol

Ligand: atorvastatin lactone (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 8.16 pIC50
Reference (Journal): Inhibitors of cholesterol biosynthesis. 3. Tetrahydro-4-hydroxy-6-[2-(1H-pyrrol-1-yl)ethyl]-2H-pyran-2-one inhibitors of HMG-CoA reductase. 2. Effects of introducing substituents at positions three and four of the pyrrole nucleus.
Published in: J Med Chem

Ligand: BMY-21950 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 7.89 pIC50
Reference (Journal): Relationship between tissue selectivity and lipophilicity for inhibitors of HMG-CoA reductase.
Published in: J Med Chem

Ligand: BMY 22089 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 7.62 pIC50
Reference (Journal): Synthesis, biological profile, and quantitative structure-activity relationship of a series of novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Published in: J Med Chem

Ligand: cerivastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1997)
Median affinity: 8.45 pIC50
Reference (Journal): Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Published in: Am J Cardiol

Ligand: cerivastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1997)
Primary target: yes
Median affinity: 8 pIC50
Reference (Journal): Three-dimensional quantitative structure (3-D QSAR) activity relationship studies on imidazolyl and N-pyrrolyl heptenoates as 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) inhibitors by comparative molecular similarity indices analysis (CoMSIA).
Published in: Bioorg Med Chem Lett

Ligand: cerivastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1997)
Primary target: yes
Median affinity: 8.239999771118164 pKi
Reference (Journal): Binding thermodynamics of statins to HMG-CoA reductase.
Published in: Biochemistry

Ligand: compound 11dd [PMID: 1656041] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 6.42 pIC50
Reference (Journal): Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids.
Published in: J Med Chem

Ligand: compound 11ff [PMID: 1656041] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 8.57 pIC50
Reference (Journal): Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids.
Published in: J Med Chem

Ligand: compound 11jj [PMID: 1656041] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 9.3 pIC50
Reference (Journal): Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids.
Published in: J Med Chem

Ligand: compound 11nn [PMID: 1656041] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 6.6 pIC50
Reference (Journal): Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids.
Published in: J Med Chem

Ligand: compound 11nn [PMID: 1656041] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 7.3 pIC50
Reference (Journal): Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids.
Published in: J Med Chem

Ligand: compound 13b [PMID: 18412317] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 9.3 pIC50
Reference (Journal): (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with reduced myotoxicity potential.
Published in: J Med Chem

Ligand: compound 13b [PMID: 2153213] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.520000457763672 pIC50
Reference (Journal): Synthesis and biological activity of new HMG-CoA reductase inhibitors. 2. Derivatives of 7-(1H-pyrrol-3-yl)-substituted-3,5-dihydroxyhept-6(E)-enoic (-heptanoic) acids.
Published in: J Med Chem

Ligand: compound 13g [PMID: 2153213] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 8.6 pIC50
Reference (Journal): Synthesis and biological activity of new HMG-CoA reductase inhibitors. 2. Derivatives of 7-(1H-pyrrol-3-yl)-substituted-3,5-dihydroxyhept-6(E)-enoic (-heptanoic) acids.
Published in: J Med Chem

Ligand: compound 13 [PMID: 1992149] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 6.32 pIC50
Reference (Journal): Relationship between tissue selectivity and lipophilicity for inhibitors of HMG-CoA reductase.
Published in: J Med Chem

Ligand: compound 16f [PMID: 18155906] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 9 pIC50
Reference (Journal): Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors.
Published in: Bioorg Med Chem Lett

Ligand: compound 17 [PMID: 15686906] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.699999809265137 pIC50
Reference (Journal): Three-dimensional quantitative structure (3-D QSAR) activity relationship studies on imidazolyl and N-pyrrolyl heptenoates as 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) inhibitors by comparative molecular similarity indices analysis (CoMSIA).
Published in: Bioorg Med Chem Lett

Ligand: compound 17 [PMID: 3701793] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 7.07 pIC50
Reference (Journal): 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 5. 6-(Fluoren-9-yl)- and 6-(fluoren-9-ylidenyl)-3,5-dihydroxyhexanoic acids and their lactone derivatives.
Published in: J Med Chem

Ligand: compound 18 [PMID: 1875346] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 8.3 pIC50
Reference (Journal): 3-Hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. 7. Modification of the hexahydronaphthalene moiety of simvastatin: 5-oxygenated and 5-oxa derivatives.
Published in: J Med Chem

Ligand: compound 18 [PMID: 8426367] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 6 pIC50
Reference (Journal): 32-Methyl-32-oxylanosterols: dual-action inhibitors of cholesterol biosynthesis.
Published in: J Med Chem

Ligand: compound 18t [PMID: 8246237] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 8.52 pIC50
Reference (Journal): HMG-CoA reductase inhibitors: design, synthesis, and biological activity of tetrahydroindazole-substituted 3,5-dihydroxy-6-heptenoic acid sodium salts.
Published in: J Med Chem

Ligand: compound 1a [PMID: 2153213] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 9.08 pIC50
Reference (Journal): Synthesis and biological activity of new HMG-CoA reductase inhibitors. 2. Derivatives of 7-(1H-pyrrol-3-yl)-substituted-3,5-dihydroxyhept-6(E)-enoic (-heptanoic) acids.
Published in: J Med Chem

Ligand: compound 1e [PMID: 2153213] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.300000190734863 pIC50
Reference (Journal): Synthesis and biological activity of new HMG-CoA reductase inhibitors. 2. Derivatives of 7-(1H-pyrrol-3-yl)-substituted-3,5-dihydroxyhept-6(E)-enoic (-heptanoic) acids.
Published in: J Med Chem

Ligand: compound 1f [PMID: 2153213] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.96999979019165 pIC50
Reference (Journal): Synthesis and biological activity of new HMG-CoA reductase inhibitors. 2. Derivatives of 7-(1H-pyrrol-3-yl)-substituted-3,5-dihydroxyhept-6(E)-enoic (-heptanoic) acids.
Published in: J Med Chem

Ligand: compound 1 [Patel et al., 1991] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 8.1 pIC50
Reference (Journal): C-2 desmethyl seco-mevinic acids. Monocyclic HMG-CoA reductase inhibitors.
Published in: Bioorg Med Chem Lett

Ligand: compound 1 [PMID: 1895299] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 8.4 pIC50
Reference (Journal): Phosphorus-containing inhibitors of HMG-CoA reductase. 2. Synthesis and biological activities of a series of substituted pyridines containing a hydroxyphosphinyl moiety.
Published in: J Med Chem

Ligand: compound 25d [PMID: 19502059] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 6.82 pIC50
Reference (Journal): Application of a 3,3-diphenylpentane skeleton as a multi-template for creation of HMG-CoA reductase inhibitors.
Published in: Bioorg Med Chem Lett

Ligand: compound 25 [PMID: 2296027] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 7.5 pIC50
Reference (Journal): Inhibitors of cholesterol biosynthesis. 2. 1,3,5-trisubstituted [2-(tetrahydro-4-hydroxy-2-oxopyran-6-yl)ethyl]pyrazoles.
Published in: J Med Chem

Ligand: compound 28 [PMID: 8246233] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 9 pIC50
Reference (Journal): Inhibitors of cholesterol biosynthesis. 1. 3,5-Dihydroxy-7-(N-imidazolyl)-6-heptenoates and -heptanoates, a novel series of HMG-CoA reductase inhibitors.
Published in: J Med Chem

Ligand: compound 29f [PMID: 17560788] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 9.07 pIC50
Reference (Journal): Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase.
Published in: Bioorg Med Chem

Ligand: compound 29 [PMID: 1527791] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 5.85 pIC50
Reference (Journal): Synthesis and biological evaluation of dihydroeptastatin, a novel inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Published in: J Med Chem

Ligand: compound 29 [PMID: 15686906] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.980000019073486 pIC50
Reference (Journal): Three-dimensional quantitative structure (3-D QSAR) activity relationship studies on imidazolyl and N-pyrrolyl heptenoates as 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) inhibitors by comparative molecular similarity indices analysis (CoMSIA).
Published in: Bioorg Med Chem Lett

Ligand: compound 29 [PMID: 2296027] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 6.8 pIC50
Reference (Journal): Inhibitors of cholesterol biosynthesis. 2. 1,3,5-trisubstituted [2-(tetrahydro-4-hydroxy-2-oxopyran-6-yl)ethyl]pyrazoles.
Published in: J Med Chem

Ligand: compound 2c [PMID: 2153213] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 9.24 pIC50
Reference (Journal): Synthesis and biological activity of new HMG-CoA reductase inhibitors. 2. Derivatives of 7-(1H-pyrrol-3-yl)-substituted-3,5-dihydroxyhept-6(E)-enoic (-heptanoic) acids.
Published in: J Med Chem

Ligand: compound 2d [PMID: 2153213] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 9.57 pIC50
Reference (Journal): Synthesis and biological activity of new HMG-CoA reductase inhibitors. 2. Derivatives of 7-(1H-pyrrol-3-yl)-substituted-3,5-dihydroxyhept-6(E)-enoic (-heptanoic) acids.
Published in: J Med Chem

Ligand: compound 2 [Dreyer et al., 1991] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.520000457763672 pKi
Reference (Journal): Phosphinic acid inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme a reductase.
Published in: Bioorg Med Chem Lett

Ligand: compound 2f [PMID: 2153213] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.739999771118164 pIC50
Reference (Journal): Synthesis and biological activity of new HMG-CoA reductase inhibitors. 2. Derivatives of 7-(1H-pyrrol-3-yl)-substituted-3,5-dihydroxyhept-6(E)-enoic (-heptanoic) acids.
Published in: J Med Chem

Ligand: compound 2g [PMID: 2296036] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 9 pIC50
Reference (Journal): Synthesis and biological activity of new HMG-CoA reductase inhibitors. 1. Lactones of pyridine- and pyrimidine-substituted 3,5-dihydroxy-6-heptenoic (-heptanoic) acids.
Published in: J Med Chem

Ligand: compound 2t [PMID: 2296036] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 8.32 pIC50
Reference (Journal): Synthesis and biological activity of new HMG-CoA reductase inhibitors. 1. Lactones of pyridine- and pyrimidine-substituted 3,5-dihydroxy-6-heptenoic (-heptanoic) acids.
Published in: J Med Chem

Ligand: compound 33 [PMID: 17574412] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 9.7 pIC50
Reference (Journal): Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors.
Published in: Bioorg Med Chem Lett

Ligand: compound 35 [PMID: 8246233] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 8.59 pIC50
Reference (Journal): Inhibitors of cholesterol biosynthesis. 1. 3,5-Dihydroxy-7-(N-imidazolyl)-6-heptenoates and -heptanoates, a novel series of HMG-CoA reductase inhibitors.
Published in: J Med Chem

Ligand: compound 3 [Dreyer et al., 1991] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.800000190734863 pKi
Reference (Journal): Phosphinic acid inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme a reductase.
Published in: Bioorg Med Chem Lett

Ligand: compound 3h [PMID: 8246234] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 9.52 pIC50
Reference (Journal): Inhibitors of cholesterol biosynthesis. 2. 3,5-Dihydroxy-7-(N-pyrrolyl)-6-heptenoates, a novel series of HMG-CoA reductase inhibitors.
Published in: J Med Chem

Ligand: compound 3j [PMID: 2231594] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 8.92 pIC50
Reference (Journal): Phosphorus-containing inhibitors of HMG-CoA reductase. 1. 4-[(2-arylethyl)hydroxyphosphinyl]-3-hydroxy-butanoic acids: a new class of cell-selective inhibitors of cholesterol biosynthesis.
Published in: J Med Chem

Ligand: compound 3k [PMID: 2231594] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 8.42 pIC50
Reference (Journal): Phosphorus-containing inhibitors of HMG-CoA reductase. 1. 4-[(2-arylethyl)hydroxyphosphinyl]-3-hydroxy-butanoic acids: a new class of cell-selective inhibitors of cholesterol biosynthesis.
Published in: J Med Chem

Ligand: compound 3q [PMID: 2231594] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 8.72 pIC50
Reference (Journal): Phosphorus-containing inhibitors of HMG-CoA reductase. 1. 4-[(2-arylethyl)hydroxyphosphinyl]-3-hydroxy-butanoic acids: a new class of cell-selective inhibitors of cholesterol biosynthesis.
Published in: J Med Chem

Ligand: compound 3u [PMID: 2231594] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 8.68 pIC50
Reference (Journal): Phosphorus-containing inhibitors of HMG-CoA reductase. 1. 4-[(2-arylethyl)hydroxyphosphinyl]-3-hydroxy-butanoic acids: a new class of cell-selective inhibitors of cholesterol biosynthesis.
Published in: J Med Chem

Ligand: compound 41 [PMID: 17574411] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 9.52 pIC50
Reference (Journal): Design and synthesis of novel, conformationally restricted HMG-CoA reductase inhibitors.
Published in: Bioorg Med Chem Lett

Ligand: compound 42 [PMID: 17574411] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 8.72 pIC50
Reference (Journal): Design and synthesis of novel, conformationally restricted HMG-CoA reductase inhibitors.
Published in: Bioorg Med Chem Lett

Ligand: compound 4 [Balasubramanian et al., 1992] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 5.4 pIC50
Reference (Journal): HMG-CoA Reductase Inhibitors 4. Tetrazole series: Conformational contraints and structural requirements at the hydrophobic domain.
Published in: Bioorg Med Chem Lett

Ligand: compound 4d [PMID: 2296036] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 8.52 pIC50
Reference (Journal): Synthesis and biological activity of new HMG-CoA reductase inhibitors. 1. Lactones of pyridine- and pyrimidine-substituted 3,5-dihydroxy-6-heptenoic (-heptanoic) acids.
Published in: J Med Chem

Ligand: compound 4ff [PMID: 1656041] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 8.75 pIC50
Reference (Journal): Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids.
Published in: J Med Chem

Ligand: compound 4i [PMID: 2296036] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 6.43 pIC50
Reference (Journal): Synthesis and biological activity of new HMG-CoA reductase inhibitors. 1. Lactones of pyridine- and pyrimidine-substituted 3,5-dihydroxy-6-heptenoic (-heptanoic) acids.
Published in: J Med Chem

Ligand: compound 4p [PMID: 1895299] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 9.26 pIC50
Reference (Journal): Phosphorus-containing inhibitors of HMG-CoA reductase. 2. Synthesis and biological activities of a series of substituted pyridines containing a hydroxyphosphinyl moiety.
Published in: J Med Chem

Ligand: compound 4rr [PMID: 1656041] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 6 pIC50
Reference (Journal): Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids.
Published in: J Med Chem

Ligand: compound 50 [PMID: 18072721] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 8.82 pIC50
Reference (Journal): Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemia.
Published in: J Med Chem

Ligand: compound 5ab [PMID: 8246233] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 9 pIC50
Reference (Journal): Inhibitors of cholesterol biosynthesis. 1. 3,5-Dihydroxy-7-(N-imidazolyl)-6-heptenoates and -heptanoates, a novel series of HMG-CoA reductase inhibitors.
Published in: J Med Chem

Ligand: compound 6a [Patil et al., 1989] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 6.3 pIC50
Reference (Journal): Novel Acetylenic Acids from the Root Bark of Paramacrolobium caeruleum: Inhibitors of 3-Hydroxy-3-methyl-glutaryl Coenzyme A Reductase.
Published in: J Nat Prod

Ligand: compound 6v [PMID: 1895299] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 8.92 pIC50
Reference (Journal): Phosphorus-containing inhibitors of HMG-CoA reductase. 2. Synthesis and biological activities of a series of substituted pyridines containing a hydroxyphosphinyl moiety.
Published in: J Med Chem

Ligand: compound 74 [PMID: 1656041] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 9 pIC50
Reference (Journal): Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids.
Published in: J Med Chem

Ligand: compound 7 [PMID: 2909732] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 8.89 pIC50
Reference (Journal): Synthesis and biological evaluation of a monocyclic, fully functional analogue of compactin.
Published in: J Med Chem

Ligand: compound 8b [PMID: 1992138] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 7.6 pIC50
Reference (Journal): Inhibitors of cholesterol biosynthesis. 4. trans-6-[2-(substituted-quinolinyl)ethenyl/ethyl]tetrahydro-4-hydroxy-2 H-pyran-2-ones, a novel series of HMG-CoA reductase inhibitors.
Published in: J Med Chem

Ligand: compound 9a [Patil et al., 1989] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 5.3 pIC50
Reference (Journal): Novel Acetylenic Acids from the Root Bark of Paramacrolobium caeruleum: Inhibitors of 3-Hydroxy-3-methyl-glutaryl Coenzyme A Reductase.
Published in: J Nat Prod

Ligand: compound 9 [PMID: 1992149] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 8.18 pIC50
Reference (Journal): Relationship between tissue selectivity and lipophilicity for inhibitors of HMG-CoA reductase.
Published in: J Med Chem

Ligand: compound 9 [PMID: 1992149] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 8.16 pIC50
Reference (Journal): Inhibitors of cholesterol biosynthesis. 6. trans-6-[2-(2-N-heteroaryl-3,5-disubstituted- pyrazol-4-yl)ethyl/ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-ones.
Published in: J Med Chem

Ligand: compound 9 [PMID: 7932551] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 6.7 pIC50
Reference (Journal): Synthesis and biological activity of bile acid-derived HMG-CoA reductase inhibitors. The role of 21-methyl in recognition of HMG-CoA reductase and the ileal bile acid transport system.
Published in: J Med Chem

Ligand: dalvastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.470000267028809 pIC50
Reference (Journal): RG 12561 (dalvastatin): a novel synthetic inhibitor of HMG-CoA reductase and cholesterol-lowering agent.
Published in: Pharmacology

Ligand: DFGYVAE (Peptide)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: no
Median affinity: 6.8 pIC50
Reference (Journal): Peptide fragmentation as an approach in modeling of an active peptide and designing a competitive inhibitory peptide for HMG-CoA reductase.
Published in: Bioorg Med Chem

Ligand: DFGYVAE (Peptide)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: no
Median affinity: 7.29 pKi
Reference (Journal): Peptide fragmentation as an approach in modeling of an active peptide and designing a competitive inhibitory peptide for HMG-CoA reductase.
Published in: Bioorg Med Chem

Ligand: fluvastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1993)
Median affinity: 8.6 pIC50
Reference (Journal): Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids.
Published in: J Med Chem

Ligand: fluvastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1993)
Primary target: yes
Median affinity: 6.559999942779541 pKi
Reference (Journal): Binding thermodynamics of statins to HMG-CoA reductase.
Published in: Biochemistry

Ligand: fluvastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1993)
Primary target: yes
Median affinity: 7.550000190734863 pIC50
Reference (Journal): Structural mechanism for statin inhibition of HMG-CoA reductase.
Published in: Science

Ligand: fluvastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1993)
Median affinity: 8.42 pIC50
Reference (Journal): Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Published in: Am J Cardiol

Ligand: fluvastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1993)
Median affinity: 8.6 pIC50
Reference (Journal): HMG-CoA reductase inhibitors: design, synthesis, and biological activity of tetrahydroindazole-substituted 3,5-dihydroxy-6-heptenoic acid sodium salts.
Published in: J Med Chem

Ligand: fluvastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1993)
Primary target: yes
Median affinity: 7.550000190734863 pKi
Reference (Journal): Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin.
Published in: Biochem Soc Trans

Ligand: fluvastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1993)
Median affinity: 8.52 pIC50
Reference (Journal): Application of a 3,3-diphenylpentane skeleton as a multi-template for creation of HMG-CoA reductase inhibitors.
Published in: Bioorg Med Chem Lett

Ligand: FPYVAE peptide [PMID: 20494585] (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 5.83 pIC50
Reference (Journal): Peptide fragmentation as an approach in modeling of an active peptide and designing a competitive inhibitory peptide for HMG-CoA reductase.
Published in: Bioorg Med Chem

Ligand: GLPDGG peptide [PMID: 20494585] (Peptide)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 4.65 pIC50
Reference (Journal): Peptide fragmentation as an approach in modeling of an active peptide and designing a competitive inhibitory peptide for HMG-CoA reductase.
Published in: Bioorg Med Chem

Ligand: lovastatin (Natural product)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1987)
Primary target: yes
Median affinity: 7.690000057220459 pIC50
Reference (Journal): Inhibitors of cholesterol biosynthesis. 6. trans-6-[2-(2-N-heteroaryl-3,5-disubstituted- pyrazol-4-yl)ethyl/ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-ones.
Published in: J Med Chem

Ligand: lovastatin (Natural product)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1987)
Median affinity: 6.3 pIC50
Reference (Journal): Design and biological evaluation of a series of thiophene-based 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors.
Published in: Bioorg Med Chem Lett

Ligand: lovastatin (Natural product)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1987)
Median affinity: 6.8 pIC50
Reference (Journal): Design and biological evaluation of a series of thiophene-based 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors.
Published in: Bioorg Med Chem Lett

Ligand: lovastatin (Natural product)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1987)
Median affinity: 8.1 pIC50
Reference (Journal): Synthesis and biological activity of new HMG-CoA reductase inhibitors. 2. Derivatives of 7-(1H-pyrrol-3-yl)-substituted-3,5-dihydroxyhept-6(E)-enoic (-heptanoic) acids.
Published in: J Med Chem

Ligand: lovastatin (Natural product)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1987)
Median affinity: 8.1 pIC50
Reference (Journal): Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids.
Published in: J Med Chem

Ligand: lovastatin (Natural product)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1987)
Primary target: yes
Median affinity: 7.300000190734863 pIC50
Reference (Journal): Synthesis and biological activity of new HMG-CoA reductase inhibitors. 2. Derivatives of 7-(1H-pyrrol-3-yl)-substituted-3,5-dihydroxyhept-6(E)-enoic (-heptanoic) acids.
Published in: J Med Chem

Ligand: lovastatin (Natural product)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1987)
Median affinity: 7.57 pIC50
Reference (Journal): The design and biological evaluation of a series of 3-hydroxy-3-methylglutaryl coenzyme a (HMG-CoA) reductase inhibitors related to dihydromevinolin.
Published in: Bioorg Med Chem Lett

Ligand: lovastatin (Natural product)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1987)
Median affinity: 7.96 pIC50
Reference (Journal): The design and biological evaluation of a series of 3-hydroxy-3-methylglutaryl coenzyme a (HMG-CoA) reductase inhibitors related to dihydromevinolin.
Published in: Bioorg Med Chem Lett

Ligand: lovastatin (Natural product)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1987)
Median affinity: 8.52 pIC50
Reference (Journal): Inhibitors of cholesterol biosynthesis. 2. 3,5-Dihydroxy-7-(N-pyrrolyl)-6-heptenoates, a novel series of HMG-CoA reductase inhibitors.
Published in: J Med Chem

Ligand: lovastatin (Natural product)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1987)
Median affinity: 7.55 pIC50
Reference (Journal): Inhibitors of cholesterol biosynthesis. 4. trans-6-[2-(substituted-quinolinyl)ethenyl/ethyl]tetrahydro-4-hydroxy-2 H-pyran-2-ones, a novel series of HMG-CoA reductase inhibitors.
Published in: J Med Chem

Ligand: lovastatin (Natural product)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1987)
Primary target: yes
Median affinity: 9.220000267028809 pKi
Reference (Journal): Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent.
Published in: Proc Natl Acad Sci USA

Ligand: mevastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: no
Median affinity: 7.52 pIC50
Reference (Journal): Inhibitors of cholesterol biosynthesis. 3. Tetrahydro-4-hydroxy-6-[2-(1H-pyrrol-1-yl)ethyl]-2H-pyran-2-one inhibitors of HMG-CoA reductase. 2. Effects of introducing substituents at positions three and four of the pyrrole nucleus.
Published in: J Med Chem

Ligand: mevastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: no
Median affinity: 9 pKi
Reference (Journal): Compactin (ML-236B) and related compounds as potential cholesterol-lowering agents that inhibit HMG-CoA reductase.
Published in: J Med Chem

Ligand: mevastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: no
Median affinity: 7.4 pIC50
Reference (Journal): Application of a 3,3-diphenylpentane skeleton as a multi-template for creation of HMG-CoA reductase inhibitors.
Published in: Bioorg Med Chem Lett

Ligand: mevastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: no
Median affinity: 8 pIC50
Reference (Journal): 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 1. Structural modification of 5-substituted 3,5-dihydroxypentanoic acids and their lactone derivatives.
Published in: J Med Chem

Ligand: mevastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: no
Median affinity: 7 pIC50
Reference (Journal): Design and biological evaluation of a series of thiophene-based 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors.
Published in: Bioorg Med Chem Lett

Ligand: mevastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: no
Median affinity: 8.85 pKi
Reference (Journal): Total synthesis and biological evaluation of structural analogues of compactin and dihydromevinolin.
Published in: J Med Chem

Ligand: mevastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: no
Median affinity: 5.94 pIC50
Reference (Journal): Design and biological evaluation of a series of thiophene-based 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors.
Published in: Bioorg Med Chem Lett

Ligand: mevastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: no
Median affinity: 6 pIC50
Reference (Journal): 3-Alkyl-3-hydroxyglutaric acids: a new class of hypocholesterolemic HMG CoA reductase inhibitors. 1.
Published in: J Med Chem

Ligand: mevastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: no
Median affinity: 6 pIC50
Reference (Journal): 3-Alkyl-3-hydroxyglutaric acids: a new class of hypocholesterolemic HMG CoA reductase inhibitors. 1.
Published in: J Med Chem

Ligand: mevastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: no
Primary target: yes
Median affinity: 7.639999866485596 pIC50
Reference (Journal): Three-dimensional quantitative structure (3-D QSAR) activity relationship studies on imidazolyl and N-pyrrolyl heptenoates as 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) inhibitors by comparative molecular similarity indices analysis (CoMSIA).
Published in: Bioorg Med Chem Lett

Ligand: mevastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: no
Median affinity: 7.6 pIC50
Reference (Journal): Inhibitors of cholesterol biosynthesis. 4. trans-6-[2-(substituted-quinolinyl)ethenyl/ethyl]tetrahydro-4-hydroxy-2 H-pyran-2-ones, a novel series of HMG-CoA reductase inhibitors.
Published in: J Med Chem

Ligand: o-hydroxyatorvastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 7.56 pKd
Reference (Journal): Thermodynamic and structure guided design of statin based inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Published in: J Med Chem

Ligand: pitavastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2009)
Primary target: no
Median affinity: 5.050000190734863 pKi
Reference (Journal): Synthesis and HMG-CoA reductase inhibition of 2-cyclopropyl-4-thiophenyl-quinoline mevalonolactones.
Published in: Bioorg Med Chem

Ligand: pravastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1991)
Median affinity: 8.38 pEC50
Reference (Journal): Synthesis and biological evaluations of condensed pyridine and condensed pyrimidine-based HMG-CoA reductase inhibitors.
Published in: Bioorg Med Chem Lett

Ligand: pravastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1991)
Median affinity: 8.16 pIC50
Reference (Journal): Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Published in: Am J Cardiol

Ligand: pravastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1991)
Primary target: yes
Median affinity: 5.860000133514404 pIC50
Reference (Journal): Synthesis and biological evaluations of condensed pyridine and condensed pyrimidine-based HMG-CoA reductase inhibitors.
Published in: Bioorg Med Chem Lett

Ligand: pravastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1991)
Primary target: yes
Median affinity: 6.989999771118164 pKi
Reference (Journal): Binding thermodynamics of statins to HMG-CoA reductase.
Published in: Biochemistry

Ligand: pravastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1991)
Median affinity: 7.89 pIC50
Reference (Journal): Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemia.
Published in: J Med Chem

Ligand: pravastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1991)
Median affinity: 8.3 pIC50
Reference (Journal): Inhibitors of cholesterol biosynthesis. 2. 3,5-Dihydroxy-7-(N-pyrrolyl)-6-heptenoates, a novel series of HMG-CoA reductase inhibitors.
Published in: J Med Chem

Ligand: pravastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1991)
Primary target: yes
Median affinity: 7.519999980926514 pIC50
Reference (Journal): Inhibitors of cholesterol biosynthesis. 6. trans-6-[2-(2-N-heteroaryl-3,5-disubstituted- pyrazol-4-yl)ethyl/ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-ones.
Published in: J Med Chem

Ligand: rosuvastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (2003)
Primary target: yes
Median affinity: 8.640000343322754 pKi
Reference (Journal): Binding thermodynamics of statins to HMG-CoA reductase.
Published in: Biochemistry

Ligand: rosuvastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (2003)
Primary target: yes
Median affinity: 8.300000190734863 pIC50
Reference (Journal): Structural mechanism for statin inhibition of HMG-CoA reductase.
Published in: Science

Ligand: rosuvastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (2003)
Primary target: yes
Median affinity: 8.510000228881836 pIC50
Reference (Journal): Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors.
Published in: Bioorg Med Chem Lett

Ligand: rosuvastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (2003)
Median affinity: 9.8 pIC50
Reference (Journal): Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Published in: Am J Cardiol

Ligand: rosuvastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (2003)
Primary target: yes
Median affinity: 8.270000457763672 pIC50
Reference (Journal): Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Published in: Am J Cardiol

Ligand: simvastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1991), EMA (2013)
Median affinity: 8.56 pIC50
Reference (Journal): Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Published in: Am J Cardiol

Ligand: simvastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1991), EMA (2013)
Median affinity: 9.05 pIC50
Reference (Journal): 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side chain ester derivatives of mevinolin.
Published in: J Med Chem

Ligand: simvastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1991), EMA (2013)
Median affinity: 8.89 pIC50
Reference (Journal): Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors.
Published in: Bioorg Med Chem Lett

Ligand: simvastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1991), EMA (2013)
Median affinity: 6.82 pIC50
Reference (Journal): Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors.
Published in: Bioorg Med Chem Lett

Ligand: simvastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1991), EMA (2013)
Median affinity: 7.31 pIC50
Reference (Journal): Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors.
Published in: Bioorg Med Chem Lett

Ligand: simvastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1991), EMA (2013)
Primary target: yes
Median affinity: 7.960000038146973 pIC50
Reference (Journal): Structural mechanism for statin inhibition of HMG-CoA reductase.
Published in: Science

Ligand: simvastatin (Synthetic organic)
Interaction type: Inhibitor
Action: Competitive
Ligand approved: yes
Approval source: FDA (1991), EMA (2013)
Primary target: yes
Median affinity: 7.920000076293945 pIC50
Reference (Journal): 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 9. The synthesis and biological evaluation of novel simvastatin analogs.
Published in: J Med Chem